Hemophilia, while not the most common bleeding disorder, is widely known among the public.

​

It is also known as the "Royal Disease" due to its presence in the European royal families of the late 19th and early 20th Century.

​

The earliest records of hemophilia date to the Talmud, a Jewish religious text from over 2000 years ago. 

​

New generations of treatment, now including gene therapy have made this a very exciting time for patients and their caregivers.  

​

Learning Objectives:

• Accurately recognize the inheritance pattern, clinical presentation and laboratory evaluation for Hemophilia

• Understand the risks and benefits of clotting factor administration for the treatment 

• Describe 3 approaches to improve the prevention of bleeding events in patients with Hemophilia

​

Presentation: Catherine McGuinn MD​

Weill Cornell Medicine

Date: October 14, 2021